Aggressive Silent GH Pituitary Tumor Resistant to Multiple Treatments, Including Temozolomide

REFERENCES

• Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:543–554.
   PubMed Web of Science ®Google Scholar
• Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER, Jr. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 2011;114:336–344.
   PubMed Web of Science ®Google Scholar
• Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine 2005;28:27–35.
   PubMedGoogle Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401–406.
   PubMed Web of Science ®Google Scholar
• Raverot G, Sturm N, de Fraipont F, Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010;95:4592–4599.
   PubMed Web of Science ®Google Scholar
• Sheehan J, Rainey J, Nguyen J, Grimsdale R, Han S. Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 2010;114:354–358.
   PubMed Web of Science ®Google Scholar
• Syro LV, Ortiz LD, Scheithauer BW, Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011;117:454–462.
   PubMed Web of Science ®Google Scholar
• Losa M, Mazza E, Terreni MR, Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 2010;163:843–851.
   PubMed Web of Science ®Google Scholar
• Bush ZM, Longtine JA, Cunningham T, Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 2010;95:E280–E290.
   Web of Science ®Google Scholar
• Raverot G, Castinetti F, Jouanneau E, Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012;76:769–775.
   PubMed Web of Science ®Google Scholar
• Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009;161:631–637.
   PubMed Web of Science ®Google Scholar
• Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2010;15:97–100.
   Web of Science ®Google Scholar
• McCormack AI, McDonald KL, Gill AJ, Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 2009;71:226–233.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Sassolas G, Loras B, Somatotropic adenomas without acromegaly. Pathol Res Pract 1991;187:943–949.
   PubMed Web of Science ®Google Scholar
• Wade AN, Baccon J, Grady MS, Judy KD, O'Rourke DM, Snyder PJ. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011;165:39–44.
   PubMed Web of Science ®Google Scholar
• Erickson D, Scheithauer B, Atkinson J, Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2009;71:92–99.
   PubMed Web of Science ®Google Scholar
• Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 2010;13:367–379.
   PubMed Web of Science ®Google Scholar
• Raverot G, Wierinckx A, Jouanneau E, Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol 2010;163:35–43.
   PubMed Web of Science ®Google Scholar
• Mindermann T, Kovacs K, Wilson CB. Changes in the immunophenotype of recurrent pituitary adenomas. Neurosurgery 1994;35:39–44.
   PubMed Web of Science ®Google Scholar
• Daems T, Verhelst J, Michotte A, Abrams P, De Ridder D, Abs R. Modification of hormonal secretion in clinically silent pituitary adenomas. Pituitary 2009;12:80–86.
   PubMed Web of Science ®Google Scholar
• Shimon I, Melmed S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82: 1675–1681.
   PubMed Web of Science ®Google Scholar
• Pinto EM, Siqueira SA, Cukier P, Fragoso MC, Lin CJ, de Mendonca BB. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome. Pituitary 2009;14:400–404.
   Web of Science ®Google Scholar
• Lania AG, Ferrero S, Pivonello R, Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab 2010;95:13–17.
   PubMed Web of Science ®Google Scholar
• Zuhur SS, Tanik C, Karaman O, MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine 2011;40:222–227.
   PubMed Web of Science ®Google Scholar
• Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 2005;5:285–296.
   PubMed Web of Science ®Google Scholar
• Salehi F, Scheithauer BW, Kros JM, MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neurooncol 2011;104:647–657.
   PubMed Web of Science ®Google Scholar
• Heaney AP. Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 2011;96:3649–3660.
   PubMed Web of Science ®Google Scholar